Netherlands· NL-e5f9d790e5be

IMBRUVICA 560 mg filmomhulde tabletten

A ibrutinib product containing ibrutinib, registered in Netherlands by Janssen-Cilag International NV. The same ATC class is registered in 13 of our 19 countries.

ATC L01EL01

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about ibrutinibAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Ibrutinib is registered in 13 of 19 countries.

Countries holding a registration under ATC L01EL01 (ibrutinib), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
8 of them publish a price we can compare per daily dose

Search ibrutinib products by name

Ibrutinib · ATC L01EL01

13 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Icelandprice
Japan
Netherlands
Norwayprice
Polandprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of ibrutinib costs, country by country.

Normalised to the WHO defined daily dose (0.42 g), the median price runs from $4.92 in France to $193.73 in Switzerland — a ×39 gap.

2 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Ibrutinib · price per daily dose (0.42 g)

USD · FX 28 Sept 2026

CH Switzerland$193.73
FR France$4.92

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: IBRUTINIB
Manufacturer: Janssen-Cilag International NV
Country: Netherlands (NL)
ATC code: L01EL01
ATC class: Ibrutinib
Defined daily dose: 0.42 g, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
EU/1/14/945

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

370 interactions on record for ibrutinib.

Graded by severity as the source publishes them — 189 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check ibrutinib against other medicines How interaction checks work

Ibrutinib · interactions on record

370 records

189 severe
177 moderate
4 minor

Most severe, free to view

AprepitantA04AD12severe
LinseedA06AC05severe
LonafarnibA16AX20severe
DicoumarolB01AA01severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ibrutinib in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ibrutinib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

Iceland · Imbruvica
Liechtenstein · Imbruvica
Norway · Imbruvica

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/fb3e71fa-7b93-442c-a106-1e657013618c
GET /v1/drugs/fb3e71fa-7b93-442c-a106-1e657013618c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/imbruvica-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Ibrutinib",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp121780",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSCARMELLOSE  NATRIUM  (E 468)",
    "IJZEROXIDE GEEL (E 172)",
    "IJZEROXIDE ROOD  (E 172)",
    "LACTOSE 1-WATER",
    "MACROGOL",
    "MAGNESIUMSTEARAAT (E 470b)",
    "NATRIUMLAURILSULFAAT",
    "POLYVINYLALCOHOL (E 1203)",
    "POVIDON K 25 (E 1201)",
    "SILICIUMDIOXIDE (E 551)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "IBRUTINIB"
  ],
  "leaflet_url": null,
  "authorised_at": "2018/06/29",
  "procedure_number": "EMEA/H/C/003791",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/14/945",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about ibrutinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console